Close

Array Biopharma (ARRY) Announces $100M Common Stock Offering

Go back to Array Biopharma (ARRY) Announces $100M Common Stock Offering

Array Biopharma (ARRY) Prices 18.4M Share Stock Offering for Proceeds of ~$115M

September 28, 2016 6:11 AM EDT

Array BioPharma Inc. (Nasdaq: ARRY) announced the pricing of an underwritten public offering of 18,400,000 shares of its common stock at a public offering price of $6.25 per share. The gross proceeds from the sale of the shares, before underwriting discounts and commissions and offering expenses, are expected to be approximately $115 million. The offering is expected to close on or about October 3, 2016, subject to customary closing conditions. Array also granted the... More

Array Biopharma (ARRY) Gives Up Earlier Gains; Falls 2%

September 27, 2016 1:04 PM EDT

Yesterday's momentum stock du jour Array Biopharma (NASDAQ: ARRY) has broken lower after opening sharply higher. Shares are down 2% after gaining 81% on Monday.

... More

Array BioPharma (ARRY) PT Raised to $8 at Jefferies

September 27, 2016 7:17 AM EDT

Jefferies analyst Eun Yang reiterated a Buy rating and raised his price target on Array BioPharma (NASDAQ: ARRY) to $8.00 (from $7.00) following successful Phase 3 COLUMBUS results yesterday.

Yang commented, "Given historical MEKi/BRAFi combo data in BRAFm melanoma, positive Ph3 COLUMBUS data is... More

Array Biopharma (ARRY) Adds to Gains; Shares Up 70%

September 26, 2016 2:03 PM EDT

Array Biopharma (NASDAQ: ARRY) is pushing to the highs of the session. Shares are now up 70% after the company announced positive top-line results of the Phase III "COLUMBUS" trial evaluating the combination of binimetinib with encorafenib compared to Roche's vemurafenib in patients with BRAF+ metastatic melanoma.

... More

Array BioPharma (ARRY) PT Raised to $9 at Leerink Partners Following 'Impressive' Phase III Trial

September 26, 2016 12:49 PM EDT

Leerink Partners analyst Michael Schmidt reiterated an Outperform rating and raised his price target on Array BioPharma (NASDAQ: ARRY) to $9.00 (from $6.00) after the company announced positive top-line results of the Phase III "COLUMBUS" trial evaluating the combination of binimetinib with encorafenib compared to Roche's vemurafenib in patients with BRAF+ metastatic... More

Array Biopharma (ARRY), Pierre Fabre Announce Encorafenib Combo Phase 3 Met Primary Endpoint in BRAF-Mutant Melanoma

September 26, 2016 7:01 AM EDT

Array BioPharma (Nasdaq: ARRY) and Pierre Fabre jointly announced top-line results from Part 1 of the Phase 3 COLUMBUS (Combined LGX818 Used with MEK162 in BRAF Mutant Unresectable Skin Cancer) study evaluating LGX818 (encorafenib), a BRAF inhibitor, and MEK162... More